These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27882820)

  • 1. Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
    Bergqvist M; Holgersson G; Bondarenko I; Grechanaya E; Maximovich A; Andor G; Klockare M; Thureson M; Jerling M; Harmenberg J
    Acta Oncol; 2017 Mar; 56(3):441-447. PubMed ID: 27882820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.
    Ekman S; Harmenberg J; Frödin JE; Bergström S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund Å; Alvfors C; Ståhl B; Bergqvist M
    Acta Oncol; 2016; 55(2):140-8. PubMed ID: 26161618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
    Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
    Holgersson G; Bergström S; Harmenberg J; Ringbom M; Klockare M; Jerling M; Ekman S; Lundström KL; Koyi H; Brandén E; Larsson O; Bergqvist M
    Med Oncol; 2015 Apr; 32(4):129. PubMed ID: 25794491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
    Ohyanagi F; Yanagitani N; Kudo K; Kawano Y; Sakatani T; Tanimoto A; Nishizawa H; Horiike A; Hagiwara S; Horai T; Nishio M
    Anticancer Res; 2014 Sep; 34(9):5153-8. PubMed ID: 25202107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
    Karavasilis V; Kosmidis P; Syrigos KN; Mavropoulou P; Dimopoulos MA; Kotoula V; Pectasides D; Boukovinas I; Klouvas G; Kalogera-Fountzila A; Papandreou CN; Fountzilas G; Briasoulis E
    Anticancer Res; 2014 Oct; 34(10):5649-55. PubMed ID: 25275069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
    Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
    Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
    Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
    J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Lopes G; Rosado MF; Negret LM; Rocha-Lima C; Tolba K; Farfan N; Hamilton-Nelson K; Silva O; Roman E
    Lung Cancer; 2006 Sep; 53(3):347-53. PubMed ID: 16844257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
    J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
    Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
    J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.